ALKAL2 and neuroblastoma: Together, these results indicate that aberrant regulation of the ALKAL2 ligand can drive NB, and most importantly suggest that a proportion of “ALK mutation‐negative” NB patients may also benefit from ALK TKI‐based therapeutic intervention.